Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03547050 · ClinicalTrials.gov registry record
Rolandic Epilepsy Genomewide Association International Study
A clinical trial, sponsored by King's College London.
- Completed
- Registry status
- 210
- Enrollment target
NCT03547050: Completed study, sponsored by King's College London.
NCT03547050 is a clinical trial that has completed, run by King's College London. The registered enrollment target is 210 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03547050 has completed, sponsored by King's College London.
- COMPLETED
- Registry status
- 210 participants
- Enrollment target
Study Summary
We have discovered a small change in the genetic code which increases the risk of the brainwave abnormality that is found in rolandic epilepsy. We now wish to confirm this using a second much larger sample of patients. We will investigate the other genetic changes that cause people with the brainwave abnormality to develop seizures, as well as problems with speech, coordination, attention and learning.
Primary Outcome
We will look to see if there are changes in the genetic code that cause brainwave abnormalities close to the genetic changes that we have already discovered.
Interventions
- OTHER Blood draw
- OTHER Existing samples
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2023-06-30 |
What the finished NCT03547050 record still lists
NCT03547050 is an observational study that tracks outcomes without assigning an intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Blood draw is the first listed.
NCT03547050 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03547050 about?
NCT03547050 is a clinical study titled "Rolandic Epilepsy Genomewide Association International Study". We have discovered a small change in the genetic code which increases the risk of the brainwave abnormality that is found in rolandic epilepsy. We now wish to confirm this using a second much larger sample of patients. We will investigate the other genetic changes that cause people with the brainwav...
What is the current status of trial NCT03547050?
This trial is currently completed. The enrollment target is 210 participants. The study started on 2018-06-01. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT03547050?
The interventions under investigation include: Blood draw (OTHER), Existing samples (OTHER).
Who is sponsoring clinical trial NCT03547050?
This trial is sponsored by King's College London, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI